Preclinical News and Research

RSS

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies.

24 Aug 2010

FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial in the U.S. of its longer-acting version of human growth hormone, hGH-CTP.

24 Aug 2010

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Raptor Pharmaceutical Corp.,provides updates on timelines related to its clinical programs including the pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Aug 2010

Epilepsy Therapy Project, EF announce recipients of New Therapy Grants Program

The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation (EF) today announced the latest grant recipients of its New Therapy Grants Program, a unique joint venture of the non-profit epilepsy organizations, to advance promising epilepsy research in clinical development. The grant awards, totaling approximately $200,000 in funding, will support an experimental gene therapy that directly targets epileptogenic brain tissue, as well as an electrode system that has the potential to improve the efficacy of surgical therapies for certain epilepsy syndromes.

24 Aug 2010

SEB opens new state-of-the-art laboratory operation, R&D facility

Cryo-Cell International, Inc., one of the largest and most established leaders in stem cell innovation today announced that S-Evans Biosciences, the Company's exclusive Célle menstrual stem cell technology license partner in China has opened a new state-of-the-art laboratory operation and research & development facility located in a Hi-Tech park designated to become an epicenter for stem cell and genomics R&D; cellular therapies and stem cell cryopreservation services.

23 Aug 2010

Preclinical studies of BIND-014 to be presented at ACS National Meeting

BIND Biosciences announced today the presentation of its Medicinal Nanoengineering platform at the ACS National Meeting, including results from preclinical studies on its lead nanomedicine drug , BIND-014, scheduled to enter clinical trials later this year. BIND-014 is a targeted, polymeric nanoparticle containing the cytotoxic agent, docetaxel, which is approved in major cancer indications, including breast, prostate and lung.

23 Aug 2010

InSite Vision initiates Phase 1/2 clinical trial of ISV-303

InSite Vision Incorporated, a company developing novel ophthalmic therapeutics, today announced the initiation of a Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. ISV-303 combines a low dose of the non-steroidal anti-inflammatory bromfenac with InSite Vision's proprietary DuraSite technology.

23 Aug 2010

Pharma-Nutrition conference to highlight latest research on medical nutrition

Pharma-Nutrition, the new international scientific conference organised by Elsevier, the leading publisher of scientific, technical and medical information products and services, aims to discuss the latest research, concepts and practical applications of medical nutrition in patient treatments, disease management and patient outcomes.

21 Aug 2010

Combination of 2 FDA approved drugs eliminate HIV infection

Researchers at the University of Minnesota Academic Health Center have identified two drugs that, when combined, may serve as an effective treatment for HIV.

21 Aug 2010

Anchor Therapeutics announces initial closing of $10 million Series B financing

Anchor Therapeutics today announced an initial closing of $10 million in a Series B financing. The investment is being led by current investors TVM Capital, HealthCare Ventures and the Novartis Option Fund. The company is in continuing discussions with additional investors interested in joining the Series B. Anchor Therapeutics is focused on developing peptide drug candidates, called pepducins, that modulate G protein coupled receptors (GPCRs), particularly those historically difficult to target using standard pharmaceutical approaches.

20 Aug 2010

Cyprotex launches new in vitro toxicology service

Cyprotex PLC, the preclinical ADME Tox services company, today announces the launch of its new in vitro toxicology service, branded as Cyprotox(R). Supporting the new service is an additional 90 square metres of laboratory space at Cyprotex's Macclesfield, UK facility housing the latest technology in multi-parametric automated fluorescent imaging and cellular analysis. This gives Cyprotex's Macclesfield site the same in vitro toxicology capabilities as those of Apredica (Watertown, MA, USA), which Cyprotex acquired on 6 August 2010.

From Thermo Fisher Scientific Inc. 20 Aug 2010

Human neural stem cells restore motor function in mice with chronic spinal cord injury

StemCells, Inc. announced today the publication of new preclinical data demonstrating that the Company's proprietary human neural stem cells restore lost motor function in mice with chronic spinal cord injury. This is the first published study to show that human neural stem cells can restore mobility even when administered at time points beyond the acute phase of trauma, suggesting the prospect of treating a much broader population of injured patients than previously demonstrated.

20 Aug 2010

Cerulean Pharma to assemble scientific experts at ACS National Meeting symposium

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced it will assemble a group of leading scientific experts at the American Chemical Society's ("ACS") 240th National Meeting & Exposition for a three-day thought leadership summit on the advancement of nanotechnology in the pharmaceutical and diagnostic industries.

20 Aug 2010

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

International Stem Cell Corporation, today announced that its stem cell therapeutic programs focused on protective, transparent corneas (CytoCor™) in the front of the eye and the light-sensitive retinal tissue (CytoRet™) in the back of the eye will be formalized into a new business unit, Cytovis™.

20 Aug 2010

UCI study is first to show reversal of long-term hind-limb paralysis

A UC Irvine study is the first to demonstrate that human neural stem cells can restore mobility in cases of chronic spinal cord injury, suggesting the prospect of treating a much broader population of patients.

20 Aug 2010

Muscle mass plays key role in cancer survival: Research

In the vast majority of patients with advanced cancer, their muscles will gradually waste away for reasons that have never been well understood. Now, researchers reporting in the August 20 issue of Cell, a Cell Press Publication, have found some new clues and a way to reverse that process in mice. What's more, animals with cancer that received the experimental treatment lived significantly longer, even as their tumors continued to grow.

20 Aug 2010

Cetero Research expands Clinical Dermatology and Transdermal Delivery System services

Cetero Research, the leading early stage contract research organization (CRO), today announced the expansion of multiple Clinical Dermatology and Transdermal Delivery System (TDDS) services to four Cetero clinical facilities.

20 Aug 2010

Second round of abstract submission for International Symposium on MR-guided Focused Ultrasound

Due to overwhelming response from researchers, a second round of abstract submissions for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound will open on Monday, August 23, 2010, nine days earlier than previously announced. The submission deadline will be moved forward to Monday, September 6, 2010.

19 Aug 2010

Study finds burnout progressively develops among medical students

More than 40 percent of third-year medical students have symptoms of moderate to severe burnout, according to a study in the August Southern Medical Journal, official journal of the Southern Medical Association.

19 Aug 2010

Dr. Hartung receives Agilent Thought Leader Award for developmental neurotoxicity research

Agilent Technologies Inc. and the Agilent Foundation today announced that Dr. Thomas Hartung has received an Agilent Thought Leader Award in support of his research for the use of toxicity pathways to predict developmental neurotoxicity. This work could help identify possible contributions of chemicals to disorders such as autism and attention hyperactivity disorders.

19 Aug 2010